BCM
ALDR

BlueCrest Capital Management’s Alder Biopharmaceuticals ALDR Stock Holding History

BlueCrest Capital Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-23,023
Closed -$364K – 1926
2018
Q2 		$364K Buy
+23,023
New +$350K 0.01% 1004

Other funds holding ALDR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlueCrest Capital Management's ALDR Position: Q3 2018 in Review

BlueCrest Capital Management sold out of Alder Biopharmaceuticals (ALDR) in Q3 2018, closing a stake of 23,023 shares — an estimated $364K sold.

BlueCrest Capital Management first reported a position in ALDR in Q2 2018 and held it in 1 quarter. The position peaked at $364K in Q2 2018. 127 funds tracked by Wall St. Rank hold ALDR as of Q3 2018.

  • BlueCrest Capital Management reported no remaining Alder Biopharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 23,023 Alder Biopharmaceuticals shares in Q3 2018, an estimated $364K.
  • BlueCrest Capital Management first reported a position in Alder Biopharmaceuticals in Q2 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Alder Biopharmaceuticals position peaked at $364K in Q2 2018.
  • 127 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2018.

Based on BlueCrest Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.